Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

A CRISPR-Cas9 system for simultaneously knocking out Kras gene and EGFR gene and its application

A gene and DNA sequence technology, applied in the field of CRISPR-Cas9 system, to achieve the effects of simple operation, high knockout efficiency and multiple options

Active Publication Date: 2019-12-17
浙江卫未生物医药科技有限公司
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

There is no report on the CRISPR-Cas9 system that simultaneously knocks out the KRAS gene and the EGFR gene

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A CRISPR-Cas9 system for simultaneously knocking out Kras gene and EGFR gene and its application
  • A CRISPR-Cas9 system for simultaneously knocking out Kras gene and EGFR gene and its application
  • A CRISPR-Cas9 system for simultaneously knocking out Kras gene and EGFR gene and its application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0034] 1. sgRNA design

[0035]According to the human KRAS gene sequence (Sequence ID: NM_033360.3) and EGFR gene sequence (Sequence ID: NM_201282.1) given in GeneBank, 10 sgRNAs were designed respectively (the corresponding DNA sequences are shown in SEQ ID NO.1-10 respectively) and shown in SEQ ID NO.11-20). The sgRNAs of the two genes are all targeted at their exon regions, and blasted in UCSC or NCBI to ensure the uniqueness of their target sequences. Of the 10 sgRNAs designed separately, only 2 can effectively knock out KRAS and EGFR, and the first kras-sg1 (corresponding DNA sequence shown in SEQ ID NO.1) and egfr-sg1 (corresponding DNA sequence Shown in SEQ ID NO.11) to explain in detail, such as figure 1 and figure 2 shown.

[0036] 2. Construction of sgRNA oligonucleotide double strands

[0037] Add CACC to the 5' end of the upstream primer of the determined KRAS target sequence, and add AAAC to the 5' end of the downstream primer, so that the double-stranded DN...

Embodiment 2

[0063] T7EN1 digestion experiment:

[0064] The cells collected in Example 1 were lysed, the genomic DNA was extracted with a kit, and finally dissolved in 50 μL of deionized water.

[0065] According to the KRAS gene sequence and EGFR gene sequence published by GenBank, specific primers were designed with Primer 5.0 software, as shown in Table 2:

[0066] Table 2

[0067]

[0068] Use the kit to extract part of the genomic DNA of the cells, and use the extracted genomic DNA of the cells as a template to amplify the target fragment using the specific primers designed in Table 2. Amplification system: 10 μL of 2×PCR Mix, 1 μL of genomic DNA, 1 μL of upstream and downstream primers, plus dd H 2 0 to 20 μL. Reaction program: pre-denaturation at 94°C for 5 minutes; denaturation at 94°C for 30 seconds, annealing at 60°C for 30 seconds, extension at 72°C for 35 seconds, a total of 30 cycles; extension at 72°C for 10 minutes; storage at 4°C.

[0069] 100ng of the purified PCR ...

Embodiment 3

[0071] Western blot experiment:

[0072] Take 1x10 lung cancer cells before and after knockout of KRAS and EGFR 6 After the cells were collected, 20 μL of lysate (50 mM HEPES, PH7.0, 1% NP-40, 5 mM EDTA, 450 mM Nacl, 10 mM Na pyrophosphate and 50 mM NaF) was added, and various fresh inhibitors (1 mM Na orthovanadate, 1 mM PMSF, 10 μg / ml Aprotinin, Leupeptin, pepstatin). After sonication at room temperature, add 1% mercaptoethanol, place at 100°C for 5 minutes and boil for denaturation. On SDS-PAGE gel, load 10 μL of sample per well. After electrophoresis, transfer the protein sample to a nitrocellulose membrane. After transfer, the membrane was washed once with TBST, blocked with 5% skimmed milk powder for 1 hour, washed once with TBST, and the diluted primary antibody was hybridized with the membrane for 2 hours at room temperature or overnight at 4°C. After washing three times with TTBS, the diluted secondary antibody was hybridized with the membrane at room temperature f...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats)-Cas9 system capable of simultaneously knocking out KRAS genes and EGFR genes. The system comprises sgRNA for specifically targeting KRAS genes and sgRNA for specifically targeting EGFR genes, wherein a corresponding DNA sequence of the sgRNA for specifically targeting KRAS genes is shown as SEQ ID NO.1 or / and SEQ ID NO.2; and a corresponding DNA sequence of the sgRNA for specifically targeting EGFR genes is shown as SEQ ID NO.11 or / and SEQ ID NO.12. The invention further discloses application of the system in preparation of medicines for treating cancers. The CRISPR-Cas9 system disclosed by the invention is capable of simultaneously and efficiently knocking out two cancer driving factors KRAS and EGFR which are highly-expressed in lung cancer. The system is simple in operation and high in knockout efficiency and is expected to be applied to treatment of the lung cancer. The system disclosed by the invention is applicable to multiple cancers with abnormal expressions of the EGFR and KRAS.

Description

technical field [0001] The invention relates to the technical field of genetic engineering, in particular to a CRISPR-Cas9 system for simultaneously knocking out KRAS gene and EGFR gene and its application. Background technique [0002] Lung cancer is currently the malignant tumor with the highest morbidity and mortality in the world, and the morbidity and mortality of lung cancer worldwide are on the rise. In my country, with the acceleration of industrialization, serious environmental pollution and aging population, the cancer burden of lung cancer is increasing day by day. Lung cancer can be divided into two major categories based on histopathology: non-small cell lung cancer (NSCLC, 85%) and small cell lung cancer (SCLC, 15%), the treatment of which remains one of the most challenging tasks in the medical field. [0003] Tumor cells continue to grow under the action of driver genes and are highly sensitive to the inhibition of driver genes, among which KRAS and EGFR are...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C12N15/90C12N9/22A61K48/00A61K31/713A61P35/00
CPCA61K31/713C07K14/71C07K14/82C12N9/22C12N15/102C12N15/907
Inventor 陈锦阳邓兆群
Owner 浙江卫未生物医药科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com